Safety of COVID-19 vaccine: A meta-analysis

Q4 Medicine 中国循证医学杂志 Pub Date : 2021-01-01 DOI:10.7507/1672-2531.202102056

C. Liu, Yaolong Chen, S. Zhao, S. Dong, Y. Zhang, Y. Zhao, Q. Zhu, H. Jin

{"title":"Safety of COVID-19 vaccine: A meta-analysis","authors":"C. Liu, Yaolong Chen, S. Zhao, S. Dong, Y. Zhang, Y. Zhao, Q. Zhu, H. Jin","doi":"10.7507/1672-2531.202102056","DOIUrl":null,"url":null,"abstract":"Objective To systematically review the safety of different types of COVID-19 vaccines in the population. Methods Web of Science, PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and CBM databases were electronically searched to collect randomized controlled trials (RCTs) which reported safety of COVID-19 vaccines in population. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed by using RevMan 5.4 software. Results A total of 5 RCTs involving 2 431 subjects were included. The results of the meta-analysis showed that COVID-19 vaccines developed more fever symptoms than placebo (RR=2.21, 95%CI 1.38 to 3.54, P=0.000 9). However, there was no significant difference in the incidence of adverse reactions (RR=1.28, 95%CI 0.96 to 1.70, P=0.10), injection site adverse reactions (RR=1.47, 95%CI 0.65 to 3.36, P=0.36) and systemic adverse reactions (RR=0.96, 95%CI 0.78 to 1.17, P=0.66) between two groups. Conclusions Current evidence shows that COVID-19 vaccines are sufficiently safe. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions. © 2021 West China University of Medical Science. All rights reserved.","PeriodicalId":39892,"journal":{"name":"中国循证医学杂志","volume":"21 1","pages":"676-682"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国循证医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7507/1672-2531.202102056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To systematically review the safety of different types of COVID-19 vaccines in the population. Methods Web of Science, PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and CBM databases were electronically searched to collect randomized controlled trials (RCTs) which reported safety of COVID-19 vaccines in population. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed by using RevMan 5.4 software. Results A total of 5 RCTs involving 2 431 subjects were included. The results of the meta-analysis showed that COVID-19 vaccines developed more fever symptoms than placebo (RR=2.21, 95%CI 1.38 to 3.54, P=0.000 9). However, there was no significant difference in the incidence of adverse reactions (RR=1.28, 95%CI 0.96 to 1.70, P=0.10), injection site adverse reactions (RR=1.47, 95%CI 0.65 to 3.36, P=0.36) and systemic adverse reactions (RR=0.96, 95%CI 0.78 to 1.17, P=0.66) between two groups. Conclusions Current evidence shows that COVID-19 vaccines are sufficiently safe. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions. © 2021 West China University of Medical Science. All rights reserved.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19疫苗的安全性:一项meta分析

目的系统评价不同类型新型冠状病毒疫苗在人群中的安全性。方法电子检索Web of Science、PubMed、EMbase、Cochrane Library、中国知网(CNKI)、万方数据(WanFang Data)和CBM数据库，收集报道COVID-19疫苗在人群中安全性的随机对照试验(RCTs)。两名审稿人独立筛选文献、提取数据并评估纳入研究的偏倚风险。采用RevMan 5.4软件进行meta分析。结果共纳入5项随机对照试验，共纳入受试者2 431人。meta分析结果显示，新冠肺炎疫苗比安慰剂出现更多发热症状(RR=2.21, 95%CI 1.38 ~ 3.54, P= 0.0009)，但两组不良反应发生率(RR=1.28, 95%CI 0.96 ~ 1.70, P=0.10)、注射部位不良反应发生率(RR=1.47, 95%CI 0.65 ~ 3.36, P=0.36)和全身不良反应发生率(RR=0.96, 95%CI 0.78 ~ 1.17, P=0.66)差异无统计学意义。目前的证据表明，COVID-19疫苗足够安全。由于纳入研究的质量和数量有限，需要更多高质量的研究来验证上述结论。©2021华西医科大学。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中国循证医学杂志 Medicine-Medicine (all)

CiteScore

0.50

自引率

0.00%

发文量

4677

期刊介绍： The Chinese Journal of Evidence-Based Medicine is the official Chinese language journal of the Cochrane China. The journal aims to present the newest research results and promote the international understanding and development of evidence-based medicine, including decision-making, research, practice, and education. Papers in any of the following fields will be considered: editorial, commentary, systematic review, clinical trial and register, methodology, policy-making and management, drug safety, education, patient safety, and knowledge translation. The journal encourages submissions from interdisciplinary studies and all manuscripts are blind peer reviewed.